Los cocristales farmacéuticos…
273
21.
Leyssens, T.; Springuel, G.;Montis, R., Candoni, N.; Veesler, S. Importanceof Solvent
Selection for StoichiometricallyDiverseCocrystal Systems: Caffeine/MaleicAcid1:1and
2:1Cocrystals. Cryst. GrowthDes.
12
, 1520-‐1530(2012).
22.
Aitipamula, S.; Chowa, P. S.; Tan, R. B. H. (2009). Theophylline–gentisicacid
(1/1).ActaCrystallogr., Sect. E: Struct. Rep. Online
E65,
o2126-‐o2127.
23.
Karki, S.; Fabian, L.; Friscic, T.; Jones,W. PowderX-‐rayDiffractionas anEmergingMethod
toStructurallyCharacterizeOrganicSolids. Org. Lett.
9
, 3133-‐3136(2007).
24.
Chieng, N.;Hubert,M.; Saville, D.; Rades, T.; Aaltonen, J. FormationKinetics andStabilityof
Carbamazepine-‐NicotinamideCocrystalsPreparedbyMechanical Activation. Cryst. Growth
Des.
9
, 2377-‐2386(2009).
25.
Bucar, D.K.;Henry, R. F.; Lou, X.; RichardW. D;MacGillivray, L. R.; Zhang, G. G. Z. Cocrystals
of CaffeineandHydroxybenzoicAcidsComposedofMultiple
SupramolecularHeterosynthons: ScreeningviaSolution-‐MediatedPhaseTransformation
andStructural Characterization. Cryst. GrowthDes.
9
, 1932-‐1943(2009).
26.
Lu, E.; Rodríguez-‐Hornedo, N.; Suryanarayanan, R. Arapid thermalmethod for cocrystal
screening.CrystEngComm.
10
, 665-‐668(2008).
27.
Sun, C. C.;Hou, H. ImprovingMechanical Propertiesof CaffeineandMethyl GallateCrystals
byCocrystallization. Crystal GrowthDes.
8
, 1575-‐1579(2008).
28.
-‐
29.
aRemedy forCaffeineHydration. Cryst. GrowthDes.
5
, 1013-‐1021(2005).
30.
Tomaszewska, I.;Karki, S.; Shur, J.; Price, R.; Fotaki, N. Pharmaceutical characterisationand
evaluationof cocrystals: Importanceof invitrodissolutionconditions and typeof
coformer. Int. J. Pharm.
453
, 380-‐388(2013).
31.
Mohanachandran, P. S.; Sindhumol, P. G.; Kiran, T. S. Enhancement of solubilityand
dissolutionrate: Anoverview. Pharm. Globale
,
4,
1-‐10(2010).
32.
Thakuria, R.;Delori, A.; Jones,W.; Lipert,M. P.; Roy, L.; Rodríguez-‐Hornedo, N.
Pharmaceutical cocrystals andpoorlysolubledrugs. Int. J. Pharm.
453
, 101-‐125(2013).
33.
Elder, D. P.;Holm, R.;Diego, H. L. Useof pharmaceutical salts andcocrystals toaddress the
issueof poor solubility. Int. J. Pharm.
,
453
, 88-‐100(2013).
34.
Smith, A. J.; Kavuru, P.;Wojtas, L.; Zaworotko,M. J.; Shytle, R. D. CocrystalsofQuercetin
with ImprovedSolubilityandOral Bioavailability.Mol. Pharm.
8
, 1867-‐1876(2011).
35.
Hickey,M. B.; Peterson,M. L.; Scoppettuolo, L. A.;Morrisette, S. L.; Vetter, A.; Guzmán, H.,
Remenar, J. F.; Zhang, Z.; Tawa,M. D.;Haley, S.; Zaworotko,M. J.; Almarsson, O.
Performancecomparisonof aco-‐crystal of carbamazepinewithmarketedproduct. Eur. J.
of Pharm. Biopharm.,
67
, 112-‐119(2007).
36.
Zhang, T.-‐T.;Wang, H.-‐T.; Jia, J.-‐T.; Cui, X.-‐Q.; Li, Q.;Zhu, G.-‐S. Syntheses and
pharmacokineticspropertiesof an iloperidonepharmaceutical cocrystal. Inorg. Chem.
Commun.
39
, 144-‐146(2014).
37.
Trask, A. V. AnOverviewof Pharmaceutical Cocrystals as Intellectual Property.Mol.
Pharm.
4
, 301-‐309(2007).
38.
Pharmaceutical Co-‐
39.
yst. GrowthDes.
12
,
40.
Brittain, H. G. Cocrystal Systemsof Pharmaceutical Interest: 2010. Cryst. GrowthDes.
12
,
1046-‐1054(2012).
